Serdyuk S E, Gmiro V E
Department of Neurophysiology, Institute of Experimental Medicine, Russian Academy of Medical Sciences, St Petersburg, Russia.
Bull Exp Biol Med. 2007 May;143(5):611-3. doi: 10.1007/s10517-007-0195-7.
Intramuscular injection of IEM-1754, a blocker of cerebral GluR1 AMPA receptors, in doses of 0.5-3.0 mg/kg decreased the incidence of kainate-induced tonic-clonic seizures and mortality rate by 2.7-4 times. IEM-1678, an alpha3beta4 nicotinic acetylcholine receptor antagonist administered intramuscularly in a maximum dose of 3 mg/kg decreased the incidence of kainate-induced tonic-clonic seizures and mortality rate by 2.3-2.7. IEM-1460 blocking both GluR1 AMPA receptors and alpha3beta4 nicotinic acetylcholine receptors, injected intramuscularly in doses of 0.5-3.0 mg/kg produced the maximum anticonvulsant activity and 8-fold decreased the incidence of kainate-induced tonic-clonic seizures and mortality rate.
